Intuitive Surgical (NASDAQ: ISRG) is currently navigating a challenging period, with its stock price facing a 40% correction from its early 2025 highs and maintaining a high price-to-earnings (P/E) ratio of 42x, testing the resolve of even the most experienced growth investors.
A Proven History of Resilience
Despite the current drawdown, Intuitive Surgical has historically demonstrated a pattern of rebounding from significant dips to reach new valuation peaks. While the market landscape is shifting due to intensified competition from industry titans like Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ), the company’s fundamental growth trajectory remains compelling for aggressive investors.
The Evolving Landscape of Surgical Robotics
As the pioneer of the surgical robotics niche, Intuitive Surgical successfully transitioned the market from skepticism to widespread adoption. The da Vinci system is now the gold standard for minimally invasive procedures, offering clinical outcomes that have solidified its place in modern healthcare.
The Competitive Threat: Medtronic and J&J
The entry of Medtronic’s Hugo system in late 2025 and J&J’s OTTAVA robot in mid-2026 marks a new chapter of fierce competition. However, regulatory constraints play a critical role here; these systems are currently approved only for specific surgical niches. This limitation prevents an immediate, broad-scale disruption to Intuitive Surgical’s market share.
Operational Strength and Growth Metrics
Evidence of the company’s resilience is found in its recent performance. In the second quarter of 2026, Intuitive Surgical sold 468 systems, an increase from 395 in the same period of 2025. Furthermore, the total global installed base of da Vinci systems reached 11,710, a 12% year-over-year increase, while the actual number of procedures performed surged by 16%.
The Power of Recurring Revenue
The core of Intuitive Surgical’s stability lies in its business model: only 25% of revenue is derived from hardware sales. The remaining 75% is generated through services (15%) and instruments and accessories (60%). This annuity-like income stream ensures that as long as the installed base of robots is utilized, the company maintains robust cash flow, providing a significant competitive moat against new entrants.
Is the Stock Undervalued?
The healthcare market is expansive enough to support multiple players, and Intuitive Surgical’s significant head start remains a major advantage. Notably, while a 42x P/E ratio may appear steep, it sits well below the company’s five-year average of 68x, suggesting that, from a historical valuation perspective, the stock is currently trading at a relative discount.